A group of 9 experts in heart failure, ranging from leading trialists to early career clinicians, provide perspective on what they see as the biggest news in heart failure from 2023.
Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.